Damora Therapeutics reported total assets of $543.64M and total liabilities of $27.58M for the quarter ended Jun 2026. This balance sheet covers 28 quarters of results from Sep 2019 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Balance Sheet | Sep2019 | Dec2019 | Mar2020 | Jun2020 | Sep2020 | Dec2020 | Mar2021 | Jun2021 | Sep2021 | Dec2021 | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||||||||||||||
| Current Assets | ||||||||||||||||||||||||||||
| Cash & EquivalentsCash & Equiv. | 66.16M | 62.56M | 45.39M | 29.80M | 28.34M | 32.79M | 25.07M | 22.96M | 23.08M | 21.46M | 21.09M | 22.86M | 19.68M | 14.18M | 11.94M | 10.21M | 7.61M | 257.62M | 532.90M | 540.51M | ||||||||
| Short-term InvestmentsInvestments (Current) | 35.99M | 37.63M | 48.21M | 49.23M | 40.75M | 27.44M | 28.18M | 29.17M | 21.10M | 11.69M | 6.08M | |||||||||||||||||
| Cash & Current Investments | 102.14M | 100.19M | 93.60M | 79.03M | 69.08M | 60.22M | 53.25M | 52.12M | 44.18M | 33.15M | 27.17M | 22.86M | 19.68M | 14.18M | 11.94M | 10.21M | 7.61M | 257.62M | 532.90M | 540.51M | ||||||||
| Prepaid Assets | 4.86M | 9.91M | 3.43M | 3.18M | 2.12M | 3.69M | 3.88M | 3.24M | 2.88M | 3.62M | 3.37M | 2.31M | 1.50M | 2.66M | 2.98M | 2.82M | 2.18M | 2.80M | 2.51M | 3.07M | ||||||||
| Current Assets | 107.01M | 110.10M | 97.03M | 82.20M | 71.20M | 63.91M | 57.13M | 55.40M | 47.10M | 36.80M | 30.54M | 25.20M | 21.20M | 16.84M | 14.92M | 13.03M | 9.80M | 260.42M | 535.41M | 543.60M | ||||||||
| Non-Current Assets | ||||||||||||||||||||||||||||
| Property, Plant & Equipment (Net)PP&E (Net) | 0.21M | 0.20M | 0.24M | 0.20M | 0.34M | 0.36M | 0.34M | 0.33M | 0.12M | 0.08M | 0.07M | 0.07M | 0.06M | 0.06M | 0.05M | 0.05M | 0.04M | 0.04M | ||||||||||
| Long-Term Investments | 25.49M | 9.05M | 8.16M | 6.89M | 6.83M | 5.83M | 3.96M | |||||||||||||||||||||
| Other Non-Current Assets | 1.36M | 2.03M | 2.80M | 3.01M | 2.81M | 2.28M | 2.49M | 2.48M | 2.42M | 1.13M | 1.71M | 1.99M | 2.10M | 0.16M | 0.32M | 0.54M | 0.84M | 0.10M | 0.03M | 0.05M | ||||||||
| Non-Current Assets | 28.87M | 12.11M | 11.90M | 10.66M | 10.82M | 9.28M | 7.50M | 3.40M | 2.95M | 1.43M | 1.94M | 2.10M | 2.18M | 0.29M | 0.44M | 0.66M | 0.94M | 0.10M | 0.03M | 0.04M | ||||||||
| Assets | 135.87M | 122.22M | 108.93M | 92.86M | 82.03M | 73.19M | 64.63M | 58.80M | 50.05M | 38.23M | 32.48M | 27.30M | 23.38M | 17.13M | 15.37M | 13.69M | 10.74M | 260.53M | 535.44M | 543.64M | ||||||||
| Liabilities | ||||||||||||||||||||||||||||
| Current Liabilities | ||||||||||||||||||||||||||||
| Accounts Payables | 1.98M | 1.53M | 3.21M | 2.81M | 1.91M | 3.35M | 3.55M | 5.56M | 4.48M | 1.70M | 1.67M | 0.72M | 0.50M | 0.38M | 0.35M | 0.76M | 0.52M | 0.44M | 0.82M | 3.48M | ||||||||
| Payables | 1.98M | 1.53M | 3.21M | 2.81M | 1.91M | 3.35M | 3.55M | 5.56M | 4.48M | 1.70M | 1.67M | 0.72M | 0.50M | 0.38M | 0.35M | 0.76M | 0.52M | 0.44M | 0.82M | 3.48M | ||||||||
| Accumulated Expenses | 3.76M | 3.01M | 4.00M | 4.67M | 6.95M | 7.76M | 10.51M | 9.34M | 8.08M | 4.13M | 2.65M | 2.98M | 1.94M | 0.82M | 1.20M | 1.87M | 2.10M | 2.40M | 6.00M | 8.88M | ||||||||
| Total Current Liabilities | 5.74M | 4.54M | 7.21M | 7.50M | 8.90M | 11.11M | 14.10M | 14.90M | 12.60M | 5.83M | 4.32M | 3.71M | 2.44M | 1.20M | 1.60M | 2.63M | 2.62M | 20.10M | 23.81M | 27.60M | ||||||||
| Non-Current Liabilities | ||||||||||||||||||||||||||||
| Preferred Stock Liabilities | 1.36M | 1.36M | 1.34M | 1.34M | 1.34M | 1.34M | ||||||||||||||||||||||
| Operating Leases | 0.51M | 0.45M | 0.40M | 0.30M | 0.44M | 0.33M | 0.23M | 0.21M | 0.11M | 0.07M | 0.06M | 0.06M | 0.06M | 0.06M | 0.05M | |||||||||||||
| Other Non-Current Liabilities | 0.04M | 0.04M | 0.05M | 0.05M | 0.08M | 0.03M | 0.03M | |||||||||||||||||||||
| Total Non-Current Liabilities | 1.26M | 1.61M | 2.69M | 2.68M | 20.07M | 23.81M | 27.55M | |||||||||||||||||||||
| Total Liabilities | 6.25M | 4.99M | 7.62M | 7.79M | 9.30M | 11.44M | 14.30M | 15.10M | 12.67M | 5.90M | 4.32M | 3.71M | 2.44M | 1.30M | 1.66M | 2.74M | 2.73M | 20.15M | 23.84M | 27.58M | ||||||||
| Shareholder's Equity | ||||||||||||||||||||||||||||
| Common Equity | 129.62M | 117.22M | 101.31M | 85.06M | 72.73M | 61.75M | 50.33M | 43.70M | 37.38M | 32.33M | 28.16M | 23.59M | 20.93M | 15.83M | 13.71M | 10.95M | 8.01M | 240.38M | 511.60M | 516.06M | ||||||||
| Liabilities and Shareholders Equity | 135.87M | 122.22M | 108.93M | 92.86M | 82.03M | 73.19M | 64.63M | 58.80M | 50.05M | 38.23M | 32.48M | 27.30M | 23.38M | 17.13M | 15.37M | 13.69M | 10.74M | 260.53M | 535.44M | 543.64M | ||||||||
| Retained Earnings | -142.70M | -156.11M | -173.10M | -189.94M | -203.70M | -217.74M | -230.73M | -241.50M | -249.61M | -256.08M | -261.60M | -266.90M | -270.80M | -277.52M | -280.10M | -283.50M | -286.63M | -487.36M | -515.15M | -546.32M | ||||||||
| Preferred Shares | 414.91M | 131.11M | 130.00M |
Pull Damora Therapeutics's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/statements?ticker=DMRA&statement=BS&frequency=Quarter&period=all&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/statements"
params = {"ticker": "DMRA", "statement": "BS", "frequency": "Quarter", "period": "all", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/statements?ticker=DMRA&statement=BS&frequency=Quarter&period=all&api_key=YOUR_API_KEY");
const data = await res.json();